BioAlliance Pharma SA (Euronext Paris – BIO), a company dedicated to specialty and orphan oncology products, today announces two key steps in the development of its AMEP™ biotherapy with the submission to the French drug agency (Afssaps) of a phase I/II clinical trial in the metastatic melanoma and the grant of a European patent covering the product until 2022.
AMEP™ targets specific receptors (integrins), overexpressed by melanoma cells involved in tumor growth and tumor angiogenesis. Based on the results of a first phase I clinical trial showing a satisfactory safety and a signal of efficacy via local administration in man, BioAlliance Pharma pursues the development of AMEP™ with a European phase I/II trial via intramuscular route in patients with metastatic melanoma.
In addition, after Asia, BioAlliance Pharma has obtained a European patent protecting AMEP™ until 2022. This represents a new step towards the international recognition of the innovation brought by this anticancer therapy.
“The progress in its clinical development, along with the recognition of its original concept strengthen the interest of a particularly innovative therapy, developed in a consortium associating academic research, industrials and melanoma clinicians and co-financed by OSEO’s Strategic Industrial Innovation Program to the “Cancer Anti-invasive Program” (CAP)”, declares Judith Greciet, CEO of BioAlliance Pharma. “AMEP™ is one of the 3 “Orphan oncology products” portfolio in clinical phase supporting BioAlliance’s ambition to become a major player in this area”.
About metastatic melanoma
The metastatic melanoma in an invasive skin cancer of bad prognosis. Its strong therapeutic need is still unmet. World Health Organization (WHO) estimates that worldwide there are nearly 200,000 new cases of melanoma and more than 46,000 deaths annually due to melanoma.